Adapting psychedelic medicine for headache and chronic pain disorders.
Emmanuelle A. D. Schindler, Peter S. Hendricks
Expert Review of Neurotherapeutics 2023 DOI: 10.1080/14737175.2023.2246655 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Perspective Peer reviewed |
|---|---|
| Topics | LSD Psilocybin |
| Keywords | Chronic pain Headache disorders Pain disorders Transitional treatment Psychedelics hallucinogens Entheogens Long-term pain Psychedelic drugs Headaches migraine Cluster headache Alternative medicine |
| Citations | 5 |
| Key points | Argues that the standard psychedelic-assisted psychotherapy model—emphasizing large doses, subjective effects, and adjunctive therapy—may face challenges when applied to headache and chronic pain disorders, and that flexible protocols are needed. |
Abstract
While the majority of current research and development surrounds depression, demoralization, and substance use disorders, there are numerous reports of psychedelics having beneficial effects in other branches of medicine, including for headache disorders and chronic pain. This perspective reviews conventional forms of treatment for headache and other chronic pain disorders and describes historical, recent, and ongoing investigations of the therapeutic effects of psychedelics in these disorders. The first two clinical trials of psilocybin in headache disorders and recent case reports of psilocybin mushroom self-administration in chronic pain patients are described. This perspective highlights several factors related to the application of psychedelics in chronic pain disorders, comparing this with the standard psychedelic-assisted psychotherapy model of treatment. When faced with a more constricted view of psychedelic medicine that features larger doses, underscores subjective effects in the mediation of therapeutic outcomes, and requires adjunctive psychotherapy to ensure safety and efficacy, the application of psychedelics in headache and chronic pain disorders may face challenges. It will be important to allow for flexibility and adaptation in protocols to evaluate different treatment paradigms, mechanisms of action, and the range of pharmacologic and extra-pharmacologic factors that affect psychedelic treatment outcomes.
Citations in the library
Cited by 5
- Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties. Psychopharmacology May 14, 2024
- Key competencies for psychedelic treatment in real-world mental health care settings. General Hospital Psychiatry 2025
- Psychotropic Drugs Reemerging as Headache Medicines. CNS Drugs September 1, 2024
- Psilocybin and Chronic Neuropathic and Centralized Pain: Converging Mechanisms in Central Sensitization, Neuroplasticity, and Network Organization Anesthesia Research September 11, 2026
- Psychedelics and Headache Disorders: an Update. Current Neurology and Neuroscience Reports August 9, 2025
Cites 45
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
and 40 more in the library